Rare BRCA1 haplotypes including 3’UTR SNPs associated with breast cancer risk

References

• Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007; 8:255 - 267
   PubMed Web of Science ®Google Scholar
• Edlich RF, Winters KL, Lin KY. Breast cancer and ovarian cancer genetics. J Long Term Eff Med Implants 2005; 15:533 - 545
   PubMedGoogle Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature 2000; 406:747 - 752
   PubMed Web of Science ®Google Scholar
• Irvin WJ Jr, Carey LA. What is triple-negative breast cancer?. Eur J Cancer 2008; 44:2799 - 2805
   PubMed Web of Science ®Google Scholar
• Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008; 22:1233 - 1239
   PubMed Web of Science ®Google Scholar
• O'Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010; 31:961 - 967
   PubMed Web of Science ®Google Scholar
• Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26:4282 - 4288
   PubMed Web of Science ®Google Scholar
• Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010; 12:12
   Web of Science ®Google Scholar
• Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310 - 2318
   PubMed Web of Science ®Google Scholar
• Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nature Rev Cancer 2004; 4:814 - 819
   PubMed Web of Science ®Google Scholar
• Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9:86
   PubMed Web of Science ®Google Scholar
• Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006; 66:8297 - 8308
   PubMed Web of Science ®Google Scholar
• Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005; 294:1925 - 1933
   PubMed Web of Science ®Google Scholar
• Akey J, Jin L, Xiong M. Haplotypes vs. single marker linkage disequilibrium tests: what do we gain?. Eur J Hum Genet 2001; 9:291 - 300
   PubMed Web of Science ®Google Scholar
• Zhang K, Calabrese P, Nordborg M, Sun F. Haplotype block structure and its applications to association studies: Power and study designs. Am J Hum Genet 2002; 71:1386 - 1394
   PubMed Web of Science ®Google Scholar
• Cox DG, Kraft P, Hankinson SE, Hunter DJ. Haplotype analysis of common variants in the BRCA1 gene and risk of sporadic breast cancer. Breast Cancer Res 2005; 7:171 - 175
   PubMed Web of Science ®Google Scholar
• Freedman ML, Penney KL, Stram DO, Riley S, McKean-Cowdin R, Le Marchand L, et al. A haplo-type-based case-control study of BRCA1 and sporadic breast cancer risk. Cancer Res 2005; 65:7516 - 7522
   PubMed Web of Science ®Google Scholar
• Dunning AM, Chiano M, Smith NR, Dearden J, Gore M, Oakes S, et al. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Human molecular genetics 1997; 6:285 - 289
   PubMed Web of Science ®Google Scholar
• Bau DT, Fu YP, Chen ST, Cheng TC, Yu JC, Wu PE, et al. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 2004; 64:5013 - 5019
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nature reviews 2006; 6:259 - 269
   Web of Science ®Google Scholar
• Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008; 29:1306 - 1311
   PubMed Web of Science ®Google Scholar
• Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68:8535 - 8540
   PubMed Web of Science ®Google Scholar
• Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008; 29:579 - 584
   PubMed Web of Science ®Google Scholar
• Pongsavee M, Yamkamon V, Dakeng S, Oc P, Smith DR, Saunders GF, et al. The BRCA1 3′-UTR: 5711 + 421T/T_5711 + 1286T/T genotype is a possible breast and ovarian cancer risk factor. Genet Test Mol Biomarkers 2009; 13:307 - 317
   PubMed Web of Science ®Google Scholar
• Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279:915 - 921
   PubMed Web of Science ®Google Scholar
• Kidd JR, Speed WC, Pakstis AJ, Kidd KK. A 100 kb block encompassing BRCA1. (abstract/program #58) 2003; 53rd Annual Meeting of The American Society of Human Genetics November 4–8th 2003 Los Angeles, California
   Google Scholar
• Bonnen PE, Wang PJ, Kimmel M, Chakraborty R, Nelson DL. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res 2002; 12:1846 - 1853
   PubMed Web of Science ®Google Scholar
• Ribas G, Milne RL, Gonzalez-Neira A, Benitez J. Haplotype patterns in cancer-related genes with long-range linkage disequilibrium: No evidence of association with breast cancer or positive selection. Eur J Hum Genet 2008; 16:252 - 260
   PubMed Web of Science ®Google Scholar
• Cheung KH, Osier MV, Kidd JR, Pakstis AJ, Miller PL, Kidd KK. ALFRED: An allele frequency database for diverse populations and DNA polymorphisms. Nucleic Acids Res 2000; 28:361 - 363
   PubMed Web of Science ®Google Scholar
• Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Ann Oncol 2009; 20:1913 - 1927
   PubMed Web of Science ®Google Scholar
• Speed WC, Kang SP, Tuck DP, Harris LN, Kidd KK. Global variation in CYP2C8-CYP2C9 functional haplotypes. Pharmacogenomics J 2009; 9:283 - 290
   PubMed Web of Science ®Google Scholar
• Speed WC, O'Roak BJ, Tarnok Z, Barta C, Pakstis AJ, State MW, et al. Haplotype evolution of SLITRK1, a candidate gene for Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet 2008; 147:463 - 466
   Web of Science ®Google Scholar
• Yamtich J, Speed WC, Straka E, Kidd JR, Sweasy JB, Kidd KK. Population-specific variation in haplotype composition and heterozygosity at the POLB locus. DNA Repair 2009; 8:579 - 584
   PubMed Web of Science ®Google Scholar
• Anderson MA, Gusella JF. Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines. In vitro 1984; 20:856 - 858
   PubMedGoogle Scholar
• Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162 - 1169
   PubMed Web of Science ®Google Scholar
• Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978 - 989
   PubMed Web of Science ®Google Scholar